Efficacy News and Research

RSS

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

9 Apr 2015

Prolong Pharmaceuticals' SANGUINATE granted FDA Orphan Drug Designation for SCD treatment

Prolong Pharmaceuticals, LLC, a biopharmaceutical company dedicated to developing products for the treatment of anemias, cancers and their debilitating comorbidities, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its flagship product SANGUINATE for the treatment of Sickle Cell Disease (SCD).

8 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

AACN announces recipients of annual research grants

The American Association of Critical-Care Nurses announces the recipients of its annual research grants, with total available funding of $160,000.

8 Apr 2015

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.

7 Apr 2015

CXCR3 molecule is key mediator of melanoma metastasis, shows research

In a unique partnership demonstrating excellence in "team science," Dartmouth investigators from Norris Cotton Cancer Center identified a role for the molecule CXCR3 (widely known to regulate the migration of immune cells) as a key mediator of melanoma metastasis.

7 Apr 2015

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Today in JAMA Pediatrics, researchers from The Children's Hospital of Philadelphia's (CHOP) PolicyLab published the largest study to date documenting the significant risks to children's health associated with prescription antipsychotics, a powerful a class of medications used to treat mental and behavioral health disorders.

7 Apr 2015

Journal of Drugs in Dermatology publishes findings on new injectable drug ATX-101

The Journal of Drugs in Dermatology is pleased to publish findings on a new injectable drug currently under development by Kythera Biopharmaceuticals, Inc. (Westlake Village, CA) that may provide a non-surgical alternative for people with double chins.

6 Apr 2015

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

6 Apr 2015

A new amyloid-targeting treatment for Alzheimer's disease

With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.

3 Apr 2015

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer.

3 Apr 2015

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.

2 Apr 2015

Omeros announces commercial availability of Omidria in U.S.

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, announced today the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

2 Apr 2015

International researchers examine efficacy of rVSV-ZEBOV-GP Ebola vaccine

The World Health Organisation declared the Ebola virus outbreak a public health emergency in August 2014; since then the development of vaccines against Ebola virus has been fast tracked.

2 Apr 2015

Humans can get better 'gas mileage' using unpowered exoskelton

It's taken millions of years for humans to perfect the art of walking. But research results published today in the journal Nature show that humans can get better 'gas mileage' using an unpowered exoskeleton to modify the structure of their ankles. The device puts an extra spring in each human step, reducing metabolic energy consumption by 7 percent below walking in normal athletic shoes.

2 Apr 2015

Emmaus Life Sciences presents Phase 3 clinical trial of PGLG treatment for sickle cell disease

Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company’s Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.

1 Apr 2015

Combined therapy boosts growth in short children with low IGF-1

Children with short stature benefit from receiving combined treatment with growth hormone and insulin-like growth factor-1, if they have low endogenous levels of the latter, a study shows.

1 Apr 2015

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck, known as MSD outside the United States and Canada, announced today that GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada.

1 Apr 2015

Study examines efficacy of continuous UV-C robots versus pulsed xenon in preventing infection

The efficacy of continuous UV-C disinfection robots versus pulsed xenon (PU-UX) was highlighted in a recently published study of ultraviolet (UV) light disinfection systems by an influential infection prevention research team, including Curtis Donskey, M.D.

1 Apr 2015

Efficacy News and Research

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Prolong Pharmaceuticals' SANGUINATE granted FDA Orphan Drug Designation for SCD treatment

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

AACN announces recipients of annual research grants

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

CXCR3 molecule is key mediator of melanoma metastasis, shows research

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Journal of Drugs in Dermatology publishes findings on new injectable drug ATX-101

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

A new amyloid-targeting treatment for Alzheimer's disease

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Omeros announces commercial availability of Omidria in U.S.

International researchers examine efficacy of rVSV-ZEBOV-GP Ebola vaccine

Humans can get better 'gas mileage' using unpowered exoskelton

Emmaus Life Sciences presents Phase 3 clinical trial of PGLG treatment for sickle cell disease

Combined therapy boosts growth in short children with low IGF-1

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Study examines efficacy of continuous UV-C robots versus pulsed xenon in preventing infection

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News